// App-Quantinova.ai

: Triamcinolone acetonide extended-release injectable suspension (TA-ER) is associated with reduced blood glucose elevation vs. standard triamcinolone in type 2 diabetes mellitus patients with knee osteoarthritis: a randomized, blinded, parallel-group study

Researchers

Presenter

  • P.G. Conaghan

Principal Investigators

  • S.J. Russell

  • R. Sala

  • G. Habib

  • Q. Vo

  • R. Manning

  • A. Kivitz

  • Y. Davis

  • J. Lufkin

  • J.R. Johnson

  • S. Kelley

Medical Centers

  • Leeds Inst. of Rheumatic and Musculoskeletal Med., Univ. of Leeds & NIHR Leeds BioMed. Res. Ctr., Leeds, United Kingdom

  • Massachusetts Gen. Hosp. Diabetes Res. Ctr., Boston, MA, USA

  • Dexcom, Inc., Sykesville, MD, USA

  • Laniado Hosp. and Technion, Kiryat Sanz, Netanya, Israel

  • Dream Team Clinical Res., Anaheim, CA, USA

  • PMG Res. of Knoxville, Knoxville, TN, USA

  • Altoona Ctr. for Clin. Res., Duncansville, USA

  • Coastal Carolina Res. Ctr., Mt. Pleasant, SC, USA

  • Flexion Therapeutics, Inc., Burlington, MA, USA,

  • Summit Analytical, Denver, CO, USA

Locations

  • United Kingdom

  • United States

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Genetic Disorder

  • Endocrine/metabolic Diseases (ME)

Disease

  • Type 2 diabetes mellitus

  • Knee osteoarthritis

  • Diabetes

  • Osteoarthritis

  • Spondylocostal dysostosis 5

Biomarkers

  • Hemoglobin A1c

Drug/Treatment

  • Triamcinolone acetonide

  • ReadySharp-P80

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Parallel Group

Phase

  • II/III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved